Anesthesiologist in the Pain Research Unit in the Department of Anesthesia at the Toronto General Hospital in Ontario.
General practitioner practising in Toronto.
Can Fam Physician. 2017 Nov;63(11):844-852.
To provide family physicians with a practical clinical summary of the Canadian Pain Society (CPS) revised consensus statement on the pharmacologic management of neuropathic pain.
A multidisciplinary interest group within the CPS conducted a systematic review of the literature on the current treatments of neuropathic pain in drafting the revised consensus statement.
Gabapentinoids, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents for treating neuropathic pain. Tramadol and other opioids are recommended as second-line agents, while cannabinoids are newly recommended as third-line agents. Other anticonvulsants, methadone, tapentadol, topical lidocaine, and botulinum toxin are recommended as fourth-line agents.
Many pharmacologic analgesics exist for the treatment of neuropathic pain. Through evidence-based recommendations, the CPS revised consensus statement helps guide family physicians in the management of patients with neuropathic pain.
为家庭医生提供加拿大疼痛学会（CPS）修订的神经病理性疼痛药物治疗共识声明的实用临床总结。
CPS 内的一个多学科利益小组在起草修订的共识声明时，对神经病理性疼痛的当前治疗方法进行了系统的文献回顾。
加巴喷丁类、三环类抗抑郁药和 5-羟色胺-去甲肾上腺素再摄取抑制剂是治疗神经病理性疼痛的一线药物。曲马多和其他阿片类药物被推荐为二线药物，而大麻素被新推荐为三线药物。其他抗惊厥药、美沙酮、他喷他多、局部利多卡因和肉毒杆菌毒素被推荐为四线药物。
有许多药物镇痛剂可用于治疗神经病理性疼痛。通过循证推荐，CPS 修订的共识声明有助于指导家庭医生管理神经病理性疼痛患者。
